Litcius/Paper detail

Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases

Pei Shen, Yezhi Wang, Xiangxiang Jia, Pengfei Xu, Lian Qin, Xi Feng, Zhiyu Li, Zhixia Qiu

2022European Journal of Medicinal Chemistry42 citationsDOIOpen Access PDF

Topics & Concepts

Janus kinaseJAK-STAT signaling pathwayRuxolitinibCancer researchSykTofacitinibstatTyrosine kinase 2Tyrosine kinaseSTAT proteinKinaseSTAT3Signal transductionImmune systemImmunologyMedicineBiologyReceptorCell biologyPlatelet-derived growth factor receptorGrowth factorInternal medicineBone marrowMyelofibrosisRheumatoid arthritisAcute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases | Litcius